Relecotinib phosphate tablet and preparation method thereof

Through the combination of polyhydroxy compounds and colloidal additives, a stable three-dimensional network structure and surface film layer are formed, which solves the stability of the rucotinib phosphate tablets in high humidity and high temperature environments, and achieves anti-hygroscopy and resistance The effect of high temperature reduces the cost of treatment.

CN118986907AActive Publication Date: 2024-11-22QINGDAO CONSON PHARMACEUTICAL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411140533.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-22
Estimated Expiration
2044-08-19

AI Technical Summary

Technical Problem

Existing ructinib phosphate tablets are prone to hygroscopic pulverization, hydrolysis and cleavage in high humidity or high temperature environments, resulting in poor stability and increasing treatment costs.

Method used

Using the combination of polyhydroxy compounds, colloidal additives and functional additives to form an orderly three-dimensional network structure and multi-layer stacked surface film layer to enhance internal molecular intimacy and surface coverage, limit water molecules aggregation and penetration, and improve moisture absorption resistance. and high temperature resistance.

Benefits of technology

It significantly improves the stability of the rucotinib phosphate tablets, avoids hygroscopic pulverization, hydrolysis and high-temperature cracking, maintains good drug loading and carrier efficiency, and is suitable for storage in high humidity and high temperature environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention relates to the field of preparation of medicine tablets, in particular to a rucotinib phosphate tablet and a preparation method thereof. The invention discloses a rucotinib phosphate tablet which is prepared from the following raw materials in parts by mass: 5-10 parts of rucotinib phosphate, 65-75 parts of a polyhydroxy compound, 5-15 parts of a colloid aid, 2-3.5 parts of a disintegrating agent, 1-4 parts of a flow aid, 2-5 parts of an adhesive and 4-10 parts of a functional aid. The prepared rucotinib phosphate tablet has good rucotinib phosphate carrier efficiency, the tablet drug loading capacity is improved, the tablet stability of the rucotinib phosphate tablet is greatly improved, and the rucotinib phosphate tablet can be stably stored in a high-humidity and high-temperature environment and has good application prospects. The phenomena of tablet moisture absorption and pulverization, moisture absorption and hydrolysis of rucotinib phosphate and high-temperature cracking of existing tablets due to the special environment are avoided, and the application prospect is very excellent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of pharmaceutical tablet preparation, and in particular to a ruxolitinib phosphate tablet and a preparation method thereof. Background Art

[0002] The chemical name of ruxolitinib phosphate is (r)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropionitrile phosphate. It is a selective JAK1 and JAK2 inhibitor used to treat a variety of myeloproliferative diseases. Ruxolitinib phosphate tablets are mostly used for the treatment of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis, myelofibrosis after polycythemia vera (PV) and myelofibrosis after essential thrombocythemia (ET). As the first drug for the treatment of myelofibrosis, it is also the only currently approved targeted drug for the pathogenesis.

[0003] At present, in terms of clinical conditions in my country, there is an urgent need for ruxolitinib phosphate tablets, but there is a lack of technical information on ruxolitinib phosphate tablets in China, and the main source is still mainly dependent on foreign imports, which is relatively expensive, increasing the burden on patients' families. On the other hand, the existing formula of ruxolitinib phosphate tablets mostly contains ingredients such as lactose and microcrystalline cellulose, which have certain hygroscopicity and are subject to the density of the tablets themselves. If stored in a high humidity or high temperature environment, it is easy to have obvious tablets that absorb moisture and powder, ruxolitinib phosphate that absorbs moisture and hydrolyzes, and high-temperature cracking phenomena, which further increases the potential treatment costs of patients or clinics for the expensive ruxolitinib phosphate tablets.

[0004] Therefore, in order to solve the above problems, the present application provides a ruxolitinib phosphate tablet and a preparation method thereof. The ruxolitinib phosphate tablet prepared in the present application not only has a good ruxolitinib phosphate carrier efficiency and maintains a good tablet drug loading, but also greatly improves the tablet stability of the ruxolitinib phosphate tablet itself, and can be stably stored in a high humidity and high temperature environment, avoiding the tablet hygroscopic powdering, ruxolitinib phosphate hygroscopic hydrolysis and high-temperature cracking phenomena caused by the above special environment in existing tablets, and has a very excellent application prospect. Summary of the invention

[0005] In order to solve the above problems, the first aspect of the present application provides a ruxolitinib phosphate tablet, which comprises the following raw materials, in parts by mass: 5 to 10 parts of ruxolitinib phosphate, 65 to 75 parts of polyhydroxy compounds, 5 to 15 parts of colloidal additives, 2 to 3.5 parts of disintegrants, 1 to 4 parts of glidants, 2 to 5 parts of binders, and 4 to 10 parts of functional additives.

[0006] As a preferred solution, the mass ratio of the polyhydroxy compound, the colloidal auxiliary agent and the adhesive is (6.8-7.4): (0.6-1.2): (0.3-0.5).

[0007] As a preferred solution, the mass ratio of the polyhydroxy compound, the colloidal auxiliary agent and the adhesive is (7-7.2): (0.8-1.1): (0.3-0.4).

[0008] As a preferred solution, the polyhydroxy compound is a combination of sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol.

[0009] As a preferred embodiment, the mass ratio of the sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol is (1-2): (2-3): (4-5.5).

[0010] As a preferred embodiment, the mass ratio of the sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol is (1.5-1.6): (2-2.5): (4.5-5).

[0011] As a preferred solution, the colloid auxiliary agent is a composition of gum arabic, gelatin and polyoxyolefin block copolymer.

[0012] As a preferred solution, the mass ratio of gum arabic, gelatin and polyoxyolefin block copolymer is (2-2.5): (3.5-4.5): (1-1.5).

[0013] As a preferred solution, the mass ratio of gum arabic, gelatin and polyoxyolefin block copolymer is 2.2:4.3:1.

[0014] As a preferred solution, the weight average molecular weight of the gum arabic is 230,000-250,000.

[0015] As a preferred solution, the weight average molecular weight of the gelatin is 60,000-80,000.

[0016] As a preferred solution, the polyoxyolefin block copolymer is a polyoxyethylene-polyoxypropylene block copolymer.

[0017] In the present application, by using the compound use of the above-mentioned colloid auxiliary agent and polyhydroxy compound, the tablet stability of ruxolitinib phosphate tablets itself can be greatly improved, with excellent anti-hygroscopicity and high temperature stability. The colloid auxiliary agent added in the present application can form an orderly and dense three-dimensional network entanglement structure with the added polyhydroxy compound through the strong intermolecular force inside, and the flow migration speed in different systems, strengthen the intimacy of internal molecules, thereby greatly reducing the free speed of water molecules in the internal system, increasing free resistance, and greatly limiting the aggregation of water molecules in the internal system; on the other hand, the addition of colloid auxiliary agents of different molecular weights can be through the continuous phase of colloid in the formation process of tablet particles, forming a multi-layer stacked surface film layer structure, the existence of the structure can effectively cover the surface of the prepared tablet, so as to greatly reduce the formation speed of the surface hydration layer under high temperature active environment and high humidity environment, block the penetration of active molecules and water molecules to the tablet system, and limit the collision efficiency of internal molecules by film layer, and then obtain excellent high temperature and high humidity stability.

[0018] As a preferred solution, the disintegrant is at least one of sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and sodium lauryl sulfate.

[0019] As a preferred solution, the disintegrant is a combination of cross-linked sodium carboxymethyl cellulose and sodium lauryl sulfate.

[0020] As a preferred solution, the mass ratio of sodium carboxymethyl cellulose to sodium lauryl sulfate is (2-3): (0.3-0.6).

[0021] As a preferred solution, the mass ratio of sodium carboxymethyl cellulose to sodium lauryl sulfate is (2-2.5): (0.4-0.5).

[0022] As a preferred solution, the glidant is at least one of colloidal silicon dioxide, magnesium stearate, calcium stearate, microcrystalline cellulose, talc, and micro-powdered silica gel.

[0023] As a preferred solution, the glidant is a combination of magnesium stearate and talc.

[0024] As a preferred solution, the average particle size of the talc is 0.1-0.5 μm.

[0025] As a preferred embodiment, the mass ratio of magnesium stearate to talc is (3-4): (0.5-1).

[0026] As a preferred solution, the adhesive is at least one of polyvinyl pyrrolidone, gelatinized starch, polyvinyl alcohol, and hydroxypropyl methylcellulose.

[0027] As a preferred solution, the adhesive is a composition of polyvinyl pyrrolidone and polyvinyl alcohol.

[0028] As a preferred solution, the mass ratio of polyvinyl pyrrolidone to polyvinyl alcohol is (4-6): (1-1.5).

[0029] As a preferred solution, the functional additives at least include starch and surfactant.

[0030] As a preferred solution, the mass ratio of the starch material to the surfactant is (6-8): (1-2).

[0031] As a preferred solution, the surfactant is at least one of sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, alkyl glycoside, betaine, fatty acid glyceride, and lecithin.

[0032] As a preferred solution, the surfactant is a composition of sodium dodecylbenzene sulfonate and fatty acid glyceride.

[0033] As a preferred solution, the mass ratio of sodium dodecylbenzene sulfonate and fatty acid glyceride is (3-3.5): (1-1.4).

[0034] As a preferred solution, the starch material is a composition of amylopectin and amylose.

[0035] As a preferred solution, the mass ratio of amylopectin to amylose is (2-2.4): (0.8-1).

[0036] The combined effect of the starch material and surfactant added in this application can effectively improve the self-stability of the ruxolitinib phosphate tablets, and maintain a good ruxolitinib phosphate content under the premise of adding more filling raw materials. The branched starch added in this application can enhance the group connection bridging effect of its multi-branched chain on the polyhydroxyl system inside the tablet through the action of the composite surfactant, thereby strengthening the inhibitory effect of the internal molecular chain system on the active molecules under the guidance of the long helical straight-chain starch molecules, and then cooperate with the colloidal film layer wrapped in the external effect to form the entrainment phenomenon of the active molecules inside and outside, increase the steric hindrance, and thus maintain excellent stability during long-term storage.

[0037] The second aspect of the present application provides a method for preparing the above-mentioned ruxolitinib phosphate tablets, which specifically comprises the following steps: S1: mixing ruxolitinib phosphate with pure water, and evenly mixing the obtained liquid with a polyhydroxy compound, then drying to remove the pure water, hot-melt extruding the mixture, and crushing the mixture through a 200-400 mesh sieve after cooling; S2: mixing the mixture with the remaining raw materials, placing them in a dry granulator for granulation, and vacuum drying the obtained solid particles at 80-90°C; S3: after drying, tabletting the obtained solid particles using a tablet press, and obtaining the product after tableting.

[0038] The beneficial effects of this application are: 1. The ruxolitinib phosphate tablets provided in the present application not only have good ruxolitinib phosphate carrier efficiency and maintain good tablet drug loading, but also greatly improve the tablet stability of the ruxolitinib phosphate tablets themselves, and can be stably stored in a high humidity and high temperature environment, avoiding the tablet hygroscopic powdering, ruxolitinib phosphate hygroscopic hydrolysis and high-temperature cracking phenomena caused by the above-mentioned special environment of the existing tablets, and have very excellent application prospects.

[0039] 2. The present application provides a ruxolitinib phosphate tablet, which can greatly improve the tablet stability of the ruxolitinib phosphate tablet itself by using a compound of a colloidal auxiliary agent and a polyhydroxy compound, and has excellent anti-hygroscopicity and high temperature stability; the colloidal auxiliary agent can form an ordered and dense three-dimensional network entanglement structure with the added polyhydroxy compound through strong internal intermolecular forces and different flow migration speeds in the system, thereby strengthening the internal molecular intimacy, thereby greatly reducing the free speed of water molecules in the internal system, increasing the free resistance, and greatly limiting the aggregation of water molecules in the internal system; on the other hand, the addition of colloidal auxiliary agents of different molecular weights can form a multi-layer stacked surface film structure through the continuous phase action of the colloid during the formation of tablet particles. The presence of this structure can effectively cover the surface of the prepared tablet, thereby greatly reducing the formation speed of the surface hydration layer in a high-temperature active environment and a high-humidity environment, and blocking the penetration of active molecules and water molecules into the tablet system.

[0040] 3. The ruxolitinib phosphate tablets provided in the present application can effectively improve the stability of the ruxolitinib phosphate tablets through the combined effect of the added starch material and the surfactant, and maintain a good ruxolitinib phosphate content under the premise of adding more filling raw materials; the added branched starch can enhance the group connection bridging effect of its multiple branches on the polyhydroxyl system inside the tablet through the action of the composite surfactant, thereby strengthening the inhibitory effect of the internal molecular chain system on the active molecules under the guidance of the long helical straight-chain starch molecules, and then cooperate with the colloidal film layer that wraps the outside to form the internal and external encapsulation phenomenon of the active molecules, increase the steric hindrance, and thus maintain excellent stability during long-term storage. DETAILED DESCRIPTION

[0041] The following will further explain and demonstrate the technical solutions in the above invention content of this application in the form of specific implementation schemes. The following embodiments are only practical examples used to illustrate and explain the contents of the technical solutions in the specification, and should not limit the scope of the claims to be protected by this application. All technical products based on the technical solutions described in the invention content of this application should be included in the scope to be protected by this application.

[0042] In the following examples, unless otherwise specified, the raw materials are all commercially available products, or can be prepared by methods well known to those skilled in the art.

[0043] Example 1 Example 1 The first aspect provides a ruxolitinib phosphate tablet, which comprises the following raw materials, by mass: 8.5 parts of ruxolitinib phosphate, 71.8 parts of polyhydroxy compounds, 10.5 parts of colloidal additives, 2.8 parts of disintegrants, 2.2 parts of glidants, 3.6 parts of binders, and 7.5 parts of functional additives.

[0044] The polyhydroxy compound is a composition of sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol, and the mass ratio of the three is 1.55:2.2:4.65.

[0045] The colloid auxiliary agent is a composition of gum arabic, gelatin and polyoxyolefin block copolymer, and the mass ratio of the three is 2.2:4.3:1.

[0046] The polyoxyolefin block copolymer is a polyoxyethylene-polyoxypropylene block copolymer, which is a Poloxamer 188 product purchased from Shanxi Jinyang Pharmaceutical Excipients Co., Ltd.

[0047] The weight average molecular weight of gum arabic was 240,000, and the product with the corresponding molecular weight was purchased from Jiangsu Caiwei Biotechnology Co., Ltd.

[0048] The weight average molecular weight of gelatin was 72,000, and the gelatin was purchased from Hebei Pengyu Biotechnology Co., Ltd.

[0049] The disintegrant is a composition of cross-linked sodium carboxymethyl cellulose and sodium lauryl sulfate, with a mass ratio of 2.4:0.4. Cross-linked sodium carboxymethyl cellulose is purchased from Shandong Xinxiong Biotechnology Co., Ltd. as a food-grade product.

[0050] The glidant is a composition of magnesium stearate and talc, with a mass ratio of 3.2:0.8; the average particle size of the talc is 0.25 μm.

[0051] The adhesive is a composition of polyvinyl pyrrolidone and polyvinyl alcohol, and the mass ratio of the two is 5:1.2.

[0052] Polyvinyl pyrrolidone was purchased from medical grade polyvinyl pyrrolidone K90 product sold by Hebei Tuohai Biotechnology Co., Ltd.

[0053] Polyvinyl alcohol was purchased from the medical grade CP2020 product sold by Xi'an Tianzheng Pharmaceutical Excipients Co., Ltd.

[0054] The functional additive is a composition of starch material and surfactant, and the mass ratio of the two is 7:1.5.

[0055] The surfactant is a composition of sodium dodecylbenzene sulfonate and fatty acid glyceride, and the mass ratio of the two is 3.2:1.1.

[0056] The starch material is a composition of amylopectin and straight-chain starch, and the mass ratio of the two is 2.2:0.9.

[0057] Amylopectin was purchased from Wuhan Huaxiang Kejie Biotechnology Co., Ltd., with a branched content of ≥70%.

[0058] Amylose was purchased from Wuhan Huaxiang Kejie Biotechnology Co., Ltd. with an amylose content of ≥70%.

[0059] The second aspect of the present embodiment provides a preparation method of the above-mentioned ruxolitinib phosphate tablets, which specifically includes the following steps: S1: mixing ruxolitinib phosphate with 5 times the mass of pure water, and evenly mixing the obtained liquid with a polyhydroxy compound, then drying to remove the pure water, hot-melt extruding the mixture, and crushing the mixture through a 300-mesh sieve after cooling; S2: mixing the mixture with the remaining raw materials, placing them in a dry granulator for granulation, and vacuum drying the obtained solid particles at 90°C; S3: after drying, tabletting the obtained solid particles using a tablet press, and the tableting is completed.

[0060] Example 2 Example 2 The first aspect provides a ruxolitinib phosphate tablet, the raw materials of which are, by mass, 8.5 parts of ruxolitinib phosphate, 68.2 parts of polyhydroxy compounds, 12 parts of colloidal additives, 3 parts of disintegrants, 2.2 parts of glidants, 3.1 parts of binders, and 8.8 parts of functional additives.

[0061] The polyhydroxy compound is a composition of sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol, and the mass ratio of the three is 1.4:2.5:5.

[0062] The colloid auxiliary agent is a composition of gum arabic, gelatin and polyoxyolefin block copolymer, and the mass ratio of the three is 2.4:3.8:1.2.

[0063] The polyoxyolefin block copolymer is a polyoxyethylene-polyoxypropylene block copolymer, which is a Poloxamer 188 product purchased from Shanxi Jinyang Pharmaceutical Excipients Co., Ltd.

[0064] The weight average molecular weight of gum arabic was 240,000, and the product with the corresponding molecular weight was purchased from Jiangsu Caiwei Biotechnology Co., Ltd.

[0065] The weight average molecular weight of gelatin was 72,000, and the gelatin was purchased from Hebei Pengyu Biotechnology Co., Ltd.

[0066] The disintegrant is a composition of cross-linked sodium carboxymethyl cellulose and sodium lauryl sulfate, with a mass ratio of 2.4:0.4. Cross-linked sodium carboxymethyl cellulose is purchased from Shandong Xinxiong Biotechnology Co., Ltd. as a food-grade product.

[0067] The glidant is a composition of magnesium stearate and talc, with a mass ratio of 3.2:0.8; the average particle size of the talc is 0.25 μm.

[0068] The adhesive is a composition of polyvinyl pyrrolidone and polyvinyl alcohol, and the mass ratio of the two is 5:1.2.

[0069] Polyvinyl pyrrolidone was purchased from medical grade polyvinyl pyrrolidone K90 product sold by Hebei Tuohai Biotechnology Co., Ltd.

[0070] Polyvinyl alcohol was purchased from the medical grade CP2020 product sold by Xi'an Tianzheng Pharmaceutical Excipients Co., Ltd.

[0071] The functional additive is a composition of starch material and surfactant, and the mass ratio of the two is 7:1.5.

[0072] The surfactant is a composition of sodium dodecylbenzene sulfonate and fatty acid glyceride, and the mass ratio of the two is 3.2:1.1.

[0073] The starch material is a composition of amylopectin and straight-chain starch, and the mass ratio of the two is 2.2:0.9.

[0074] Amylopectin was purchased from Wuhan Huaxiang Kejie Biotechnology Co., Ltd., with a branched content of ≥70%.

[0075] Amylose was purchased from Wuhan Huaxiang Kejie Biotechnology Co., Ltd. with an amylose content of ≥70%.

[0076] The second aspect of the present embodiment provides a preparation method of the above-mentioned ruxolitinib phosphate tablets, which specifically includes the following steps: S1: mixing ruxolitinib phosphate with 5 times the mass of pure water, and evenly mixing the obtained liquid with a polyhydroxy compound, then drying to remove the pure water, hot-melt extruding the mixture, and crushing the mixture through a 300-mesh sieve after cooling; S2: mixing the mixture with the remaining raw materials, placing them in a dry granulator for granulation, and vacuum drying the obtained solid particles at 90°C; S3: after drying, tabletting the obtained solid particles using a tablet press, and the tableting is completed.

[0077] Comparative Example 1 The specific implementation of this comparative example is basically the same as that of Example 1, except that: the raw materials of ruxolitinib phosphate tablets, in parts by mass, are: 8.5 parts of ruxolitinib phosphate, 80.5 parts of polyhydroxy compounds, 2.5 parts of colloid additives, 3 parts of disintegrants, 2.2 parts of glidants, 3.1 parts of binders, and 8.8 parts of functional additives.

[0078] Comparative Example 2 The specific implementation of this comparative example is basically the same as that of Example 1, except that: the raw materials of ruxolitinib phosphate tablets, in parts by mass, are: 8.5 parts of ruxolitinib phosphate, 55.5 parts of polyhydroxy compounds, 25.5 parts of colloidal additives, 3 parts of disintegrants, 2.2 parts of glidants, 3.1 parts of binders, and 8.8 parts of functional additives.

[0079] Comparative Example 3 The specific implementation of this comparative example is basically the same as that of Example 1, except that the polyhydroxy compound is a composition of sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol, and the mass ratio of the three is 0.5:1:7.5.

[0080] Comparative Example 4 The specific implementation of this comparative example is basically the same as that of Example 1, except that the colloidal auxiliary agent is a composition of gum arabic, gelatin and polyoxyolefin block copolymer, and the mass ratio of the three is 1.2:5.8:0.5.

[0081] Comparative Example 5 The specific implementation of this comparative example is basically the same as that of Example 1, except that the mass ratio of amylopectin to amylose is 5:0.8.

[0082] Comparative Example 6 The specific implementation of this comparative example is basically the same as that of Example 1, except that the mass ratio of amylopectin to amylose is 0.6:3.5.

[0083] Performance Evaluation Total impurity content: The total impurity content of the ruxolitinib phosphate tablets prepared in the examples and comparative examples was tested. The tablet specification was 20 mg / tablet, and the test value was the average value of 10 tests and recorded in Table 1.

[0084] Dissolution: The ruxolitinib phosphate tablets (20 mg / tablet) prepared in the Example and the Comparative Example were stored in a constant temperature and humidity chamber at a normal temperature range of 25-30°C and a relative humidity of 50% for 3 months. The dissolution after normal storage was tested for 30 min. The test value was the average of 10 tests and recorded in Table 1.

[0085] High temperature and high humidity stability: The ruxolitinib phosphate tablets (20 mg / tablet) prepared in the examples and comparative examples were stored in a constant temperature and humidity chamber at a high temperature of 50-55°C and a relative humidity of 75% for 3 months. After three months, the tablets were taken out to observe whether there were any moisture absorption, cracking, powdering, or fragmentation. If so, they were recorded as unqualified, otherwise they were qualified. 100 samples were tested in each group, and the qualified rate of the test samples was recorded in Table 1. Qualified rate % = number of qualified samples / 100×100%.

[0086] Table 1 Performance test results

[0087] It can be seen from the examples and comparative examples of the present application and the data results in Table 1 that Examples 1 and 2 of the present application have obvious advantages over Comparative Examples 1 to 6 in terms of total impurities in tablets, moisture and temperature resistance, and self-stability. This is mainly due to the combined effect of the polyhydroxy compounds, colloidal additives and functional additives specified in the present application. Comparative Examples 1 to 6 did not adopt the technical solution specified in the present application, resulting in obvious disadvantages in the above-mentioned performance tests, which further proves the necessity of the technical solution specified in the present application for the technical effect of the present application and solving technical problems.

Claims

1. A ruxolitinib phosphate tablet, Features: Ruxolitinib phosphate tablets, the raw materials are, by weight: 5-10 parts of ruxolitinib phosphate, 65-75 parts of polyhydroxy compounds, 5-15 parts of colloid additives, 2-3.5 parts of disintegrants, 1-4 parts of glidants, 2-5 parts of binders, and 4-10 parts of functional additives; The mass ratio of the polyhydroxy compound, the colloid auxiliary agent and the adhesive is (6.8-7.4): (0.6-1.2): (0.3-0.5); The polyhydroxy compound is a composition of sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol; the mass ratio of sulfobutyl ether-β-cyclodextrin, sorbitol and mannitol is (1-2): (2-3): (4-5.5); The colloid auxiliary agent is a composition of gum arabic, gelatin and polyoxyolefin block copolymer; The weight average molecular weight of the gum arabic is 230,000-250,000; The weight average molecular weight of the gelatin is 60,000 to 80,000; The disintegrant is at least one of sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and sodium lauryl sulfate; The glidant is at least one of colloidal silicon dioxide, magnesium stearate, calcium stearate, microcrystalline cellulose, talc, and micro-powdered silica gel; The binder is at least one of polyvinyl pyrrolidone, gelatinized starch, polyvinyl alcohol, and hydroxypropyl methylcellulose; The functional additives at least include starch and surfactant; The mass ratio of the starch material to the surfactant is (6-8): (1-2).

2. The ruxolitinib phosphate tablets according to claim 1, Features: The mass ratio of gum arabic, gelatin and polyoxyolefin block copolymer is (2-2.5): (3.5-4.5): (1-1.5).

3. The ruxolitinib phosphate tablets according to claim 2, Features: The disintegrant is a composition of cross-linked sodium carboxymethyl cellulose and sodium lauryl sulfate.

4. The ruxolitinib phosphate tablets according to claim 3, Features: The mass ratio of the sodium carboxymethyl cellulose to sodium lauryl sulfate is (2-3): (0.3-0.6).

5. The ruxolitinib phosphate tablets according to claim 4, Features: The glidant is a composition of magnesium stearate and talc; the mass ratio of the magnesium stearate to talc is (3-4): (0.5-1).

6. The ruxolitinib phosphate tablets according to claim 5, Features: The adhesive is a composition of polyvinyl pyrrolidone and polyvinyl alcohol; the mass ratio of polyvinyl pyrrolidone to polyvinyl alcohol is (4-6): (1-1.5).

7. The ruxolitinib phosphate tablets according to claim 6, Features: The surfactant is a composition of sodium dodecylbenzene sulfonate and fatty acid glyceride; the mass ratio of the sodium dodecylbenzene sulfonate and fatty acid glyceride is (3-3.5): (1-1.4).

8. The ruxolitinib phosphate tablets according to claim 7, Features: The starch material is a composition of amylopectin and straight-chain starch.

9. The ruxolitinib phosphate tablets according to claim 8, Features: The mass ratio of the amylopectin to the amylose is (2-2.4): (0.8-1).

10. A method for preparing the ruxolitinib phosphate tablets according to any one of claims 1 to 9, Features: The specific steps include: S1: mixing ruxolitinib phosphate with pure water, and uniformly mixing the obtained liquid with a polyhydroxy compound, then drying to remove the pure water, hot-melt extruding the mixture, and crushing the mixture through a 200-400 mesh sieve after cooling; S2: mixing the mixture with the remaining raw materials, placing them into a dry granulator for granulation, and vacuum drying the obtained solid particles at 80-90° C.; S3: after the drying is completed, tabletting the obtained solid particles using a tablet press, and after the tabletting is completed, the solid particles are obtained.

Citation Information

Patent Citations

  • Relecotinib composition and application thereof

    CN115702936A

  • Composition containing paricalcitol and preparation method thereof

    CN117398397A

  • Relecotinib phosphate tablet and preparation method thereof

    CN118217255A

  • Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate

    WO2024028193A1